Skip to main content

Table 2 Cognitive performance in the AD and control groups

From: Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease

Cognitive measures

AD group (n = 30)

Control group (n = 28)

p value

MMSE

19.6 (5. 4)

28.4 (1.3)

< 0.001

CASI

72.3 (14.0)

94.2 (4.5)

< 0.001

ADAS-Cog

21.2 (10.4)

4.3 (2.8)

< 0.001

COMT

 IR-T1

3.1 (1.7)

6.7 (1.4)

< 0.001

 IR-T2

4.4 (1.6)

8.4 (1.2)

< 0.001

 IR-T3

5.2 (1.5)

9.0 (0.9)

< 0.001

 DR5

2.6 (2.1)

8.4 (1.2)

< 0.001

 DR30

1.8 (2.0)

8.6 (1.0)

< 0.001

  1. Data are presented as the mean (SD). p values were obtained using Student’s t tests for all data
  2. AD Alzheimer’s disease, MMSE Mini-Mental State Examination, CASI Cognitive Ability Screening Instrument, ADAS-Cog Alzheimer’s disease assessment scale–cognitive portion, COMT common object memory test, IR-T1 trial #1 of the immediate recall test, IR-T2 trial #2 of the immediate recall test, IR-T3 trial #3 of the immediate recall test, DR5 5-min delayed recall test, DR30 30-min delayed recall test